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Objective: This paper aims to present molecular cytogenetic and epigenetic evaluation of placental
mesenchymal dysplasia (PMD).
Materials and methods: A 33-year-old woman was referred to the hospital at 18 weeks of gestation
because of a multicystic mass in the placenta. Ultrasound showed a normal amount of amniotic ﬂuid and
a normal singleton fetus. Amniocentesis revealed a karyotype of 46,XX. Array comparative genomic
hybridization analysis of amniocytes revealed no genomic imbalance. Preterm labor and premature
rupture of the membranes occurred, and a female fetus was delivered with no structural abnormality.
The placenta was enlarged and ﬁlled with many grape-like vesicles. In the placental cystic mass, inter-
phase ﬂuorescence in situ hybridization revealed diploidy and array comparative genomic hybridization
revealed no genomic imbalance. Quantitative ﬂuorescent polymerase chain reaction (QF-PCR),
methylation-speciﬁc multiplex ligation-dependent probe ampliﬁcation (MS-MLPA), and methylation-
speciﬁc PCR were performed in the placental cystic mass.
Results: MS-MLPA analysis showed hypermethylation (methylation index ¼ 0.8) at H19 differentially
methylated region (DMR) [imprinting center 1 (IC1)] at 11p15.5 and hypomethylation (methylation
index ¼ 0.2) at KvDMR1(IC2) at 11p15.5. Methylation-speciﬁc PCR assay identiﬁed hypomethylation of
PEG1/MEST at 7q32, and hypermethylation at H19DMR and hypomethylation at KvDMR1 at 11p15.5. QF-
PCR analysis identiﬁed androgenetic/biparental mosaicism in the placenta. The placental cystic mass was
consistent with the diagnosis of PMD.
Conclusion: MS-MLPA and methylation-speciﬁc PCR are useful methods for rapid detection of epigenetic
alternations in PMD, and QF-PCR is useful in the diagnosis of androgenetic/biparental mosaicism.
Copyright  2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.f interest to declare.
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Placental mesenchymal dysplasia (PMD), which has an inci-
dence of 0.02% in pregnancy, is characterized by placentomegaly
with many grape-like vesicles, a female preponderance, the
absence of trophoblastic proliferation, the presence of a normal-
appearing fetus, fetal overgrowth or intrauterine growthby Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Prenatal ultrasound at 18 weeks of gestation shows (A) a multicystic placental mass and a normal fetal head, and (B) a multicystic mass in the placenta.
Fig. 2. (A and B) Gross appearance of the placenta with placental mesenchymal dysplasia.
Fig. 3. Interphase ﬂuorescence in situ hybridization analysis of placental cystic mass
using the bacterial artiﬁcial chromosome probes RP11-96A5 (Xp11.1; FITC green
spectrum) and RP11-25M7 (11q11; Texas red spectrum) shows two green signals and
two red signals, indicating diploidy with disomy 11 and disomy X in the placental
sample. FITC ¼ ﬂuorescein isothiocyanate.
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Wiedemann syndrome (BWS) [1e10].
Recently, androgenetic/biparental mosaicism in the placenta
has been suggested as one of the many mechanisms responsible for
PMD [11e20]. Here, we present our experience of utility of quan-
titative ﬂuorescent polymerase chain reaction (QF-PCR),
methylation-speciﬁc PCR, and methylation-speciﬁc multiplex
ligation-dependent probe ampliﬁcation (MS-MLPA) in the evalua-
tion of PMD.
Materials and methods
Clinical description
A 33-year-old, gravida 3, para 2, woman was referred to the
Mackay Memorial Hospital at 18 weeks of gestation because of a
multicystic mass in the placenta (Fig. 1). Level II ultrasound ex-
amination at 18 weeks of gestation revealed a normal amount of
amniotic ﬂuid and a normal singleton fetus with a biparietal
diameter of 4.06 cm (18.3 weeks), an abdominal circumference of
15.22 cm (20.4 weeks), and a femur length of 2.65 cm (18 weeks).
The woman underwent amniocentesis, which revealed a karyo-
type of 46,XX. Array comparative genomic hybridization analysis
of uncultured amniocytes revealed no genomic imbalance.
Thereafter, the pregnancy was eventful because of preterm labor
and premature rupture of the membranes. At 21 weeks of gesta-
tion, a 610 g female fetus was delivered with no structural ab-
normality. The placenta was enlarged and ﬁlled with many grape-
like vesicles (Fig. 2). Interphase ﬂuorescence in situ hybridization
analysis of the placental cystic mass conﬁrmed diploidy (Fig. 3).
Array comparative genomic hybridization analysis of the placental
tissue revealed no genomic imbalance. QF-PCR, MS-MLPA, andhigh-resolution melting analysis of the placental cystic mass were
performed. The total b-human chorionic gonadotrophin level in
the woman’s blood was found to be normal 2 months after
delivery.
Fig. 4. MS-MLPA analysis using SALSA MS-MLPA BWS/RSS ME030-C1 assay shows (A) H19DMR(IC1) hypermethylation (methylation index> 0.5) and KvDMR1(IC2) hypo-
methylation (methylation index< 0.5) in the present case; (B) a negative control with H19DMR(IC1) normal methylation (methylation index ¼ 0.5) and KvDMR1 normal
methylation (methylation index ¼ 0.5) in the WT; (C) a positive control with H19DMR(IC1) hypomethylation (methylation index< 0.5) and KvDMR1 normal methylation
(methylation index ¼ 0.5); and (D) a positive control with H19DMR(IC1) hypermethylation (methylation index> 0.5) and KvDMR1 hypomethylation (methylation index< 0.5).
BWS/RSS ¼ BeckwitheWiedemann syndrome/RusselleSilver syndrome; IC ¼ imprinting center; MS-MLPA ¼ methylation-speciﬁc multiplex ligation-dependent probe ampliﬁ-
cation; WT ¼ wild type.
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QF-PCR analysis was performed using genomic DNAs extracted
from the placental tissue and parental blood, as described else-
where [21]. Brieﬂy, primers speciﬁcally ﬂanking informative short
tandem repeat markers on chromosomes 11q21 (D11S2017) and
18q12.1 (D18S1369) were applied to undertake polymorphic
marker analysis and determine the parental origin of the gene
dosage change.
Methylation-speciﬁc multiplex ligation-dependent probe
ampliﬁcation
MS-MLPA analysis was performed using SALSA MS-MLPA BWS/
RusselleSilver syndrome (RSS) ME030-C1 probemix (MRC-
Holland bv, Amsterdam, The Netherlands). The ME030-C1 probe-
mix contains 13 reference probes that detect genes outside the
BWS/RSS region, 26 probes that are speciﬁc to the BWS/RSS
11p15.5 region, and two probes in the NSD1 region associated with
Sotos syndrome. The 26 probes speciﬁc to the BWS/RSS 11p15.5region will give information on copy number change to detect
deletions or duplications in the 11p15.5 region. Ten of the 26
probes speciﬁc to the BWS/RSS 11p15.5 region contain HhaI
recognition site and provide information on the methylation sta-
tus of the 11p15.5 region. The H19-associated imprinting center 1
(IC1) or differentially methylated region 1 (DMR1) (H19DMR) is
methylated on the paternal allele and unmethylated on the
maternal allele. The KCNQ1OT1-associated IC2 or DMR2 or
KvDMR1 (KvDMR) is methylated on the maternal allele and
unmethylated on the paternal allele. The methylation status of
MS-MLPA probes is calculated by dividing the normalization
constant of each probe in the HhaI treated sample by the
normalization constant of each probe in the HhaI untreated sam-
ple. Normal methylation index is 0.4e0.58 [22].
Methylation-speciﬁc PCR
The methylation-speciﬁc PCR assay can speciﬁcally distinguish
the paternal allele from the maternal allele, and identify the dif-
ferential methylation of the imprinted loci such as PEG1/MEST at
Fig. 5. PCR products from bisulﬁte-modiﬁed DNA, using an unmethylated allele-speciﬁc primer pair and a methylated allele-speciﬁc primer pair on the methylation-sensitive high-
resolution melting PCR assays. (A) PEG1/MEST at 7q32. The WT shows biparental inheritance and standard biparental methylation status. The present case shows biparental in-
heritance of chromosome 7q32 with PEG1/MEST hypomethylation. (B) H19DMR(IC1) at 11p15.5. The WT shows biparental inheritance and standard biparental methylation status.
The present case shows biparental inheritance with H19DMR(IC1) hypermethylation. (C) KvDMR1 at 11p15.5. The WT shows biparental inheritance and standard biparental
methylation status. The present case shows biparental inheritance with KvDMR1 hypomethylation. IC ¼ imprinting center; PCR ¼ polymerase chain reaction; WT ¼ wild type.
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parental samples. PEG1/MEST is expressed from the paternal chro-
mosome, and is usually methylated on the maternal chromosome
and unmethylated on the paternal chromosome. H19DMR is
expressed from the maternal chromosome, and is usually methyl-
ated on the paternal chromosome and unmethylated on the
maternal chromosome. KvDMR1 is expressed from the paternal
chromosome, and is usually methylated on the maternal chromo-
some and unmethylated on the paternal chromosome. The
assessment of DNA methylation at PEG1/MEST, H19DMR, and
KvDMR1 can be performed by bisulﬁte treatment of DNA or by
digestion with methylation-sensitive restriction enzyme. In CpG
methylation, a methyl group can be attached to cytosine (C) located
at 50 to guanine (G). After sodium bisulﬁte treatment, unmethylated
cytosine is converted to uracil, whereas methylated cytosine in the
CpG dinucleotide is resistant to sodium bisulﬁte chemical
modiﬁcation.
Results
MS-MLPA analysis of the methylation status of H19DMR(IC1)
and KvDMR1(IC2) at 11p15.5 in the placental tissue showed
hypermethylation at H19DMR(IC1) (methylation index ¼ 0.8) and
hypomethylation at KvDMR1 (methylation index ¼ 0.2; Fig. 4).
High-resolution melting analysis using a methylation-speciﬁc PCR
assay identiﬁed differential methylation of the imprinted PEG1/
MEST locus at 7q32 and the imprinted H19DMR(IC1) and
KvDMR1(IC2) loci at 11p15.5, with hypomethylation of PEG1/MEST,
hypermethylation of H19DMR(IC1), and hypomethylation at
KvDMR1(IC2) in the placenta (Fig. 5). QF-PCR analysis using mi-
crosatellite markers identiﬁed androgenetic/biparental mosaicism
with androgenetic and biparental cell lines, in approximately a ratioFig. 6. Representative electrophoretogram of quantitative ﬂuorescent polymerase
chain reaction analysis of short tandem repeat markers speciﬁc for chromosomes 11
and 18. In the placenta and umbilical cord, the marker D11S2017 (11q21) shows two
peaks (122 bp:130 bp; paternal:maternal) of unequal ﬂuorescent activity with a gene
dosage increase in the paternal allele and the marker D18S1369 (18q12.1) shows two
peaks (178 bp:194 bp; maternal:paternal) of unequal ﬂuorescent activity with a gene
dosage increase in the paternal allele.of 58:42, in the placenta and the umbilical cord, respectively
(Fig. 6). The placental cystic mass was consistent with the diagnosis
of PMD.
Discussion
The present case provides evidence that quantitative methyl-
ation assays such as MS-MLPA and methylation-speciﬁc PCR are
robust and reliable methods that can easily be applied to detect
epigenetic alternations in association with PMD, and QF-PCR is
useful in the diagnosis of parental origin and inheritance pattern
for the androgenetic cell line in the presence of androgenetic/
biparental mosaicism. In addition to androgenetic/biparental
mosaicism, PMD can be associated with BWS due to an imbalance
of imprinted gene expression of the genes CDKN1C (P57KIP2), H19,
IGF-II, KCNQ1, and KCNQ1OT1 within 11p15.5 caused by epigenetic
errors and/or chromosomal abnormalities [13,19], paternal unipa-
rental disomy 6 [23], increased angiogenesis caused by over-
expression of VEGF in case of hypoxia or hypoperfusion [8], and
abnormal expression of VEGF-D at Xp22.31 in case of X chromo-
some abnormalities [4].
Kaiser-Rogers et al [12] and Robinson et al [14] ﬁrst suggested
that androgenetic/biparental mosaicism causes PMD. In the present
case, the same haploid paternal complement in the androgenetic
cell line as in the coexisting biparental cell line indicates the origin
of a single fertilization event with endoreduplication of the
paternal genome and a mitotic division of the biparental cell to
form androgenetic/biparental mosaicism. In the placenta of the
present case, the androgenetic cell line had complete homozygosity
for a paternal genome common to the biparental cell line. Our case
represents an androgenetic/biparental mosaic pattern of M1P1/
P1P1, single sperm, single oocyte (biparental pattern MPa and
androgenetic pattern PaPa) similar to those cases reported by
Makrydimas et al [24] and Kaiser-Rogers et al [12]. Other known
androgenetic/biparental mosaic patterns include M1P1/P2P2 dis-
permic [11,14,16,25,26] and M1P1/P1P2 dispermic, single oocyte
[14].
Perinatal identiﬁcation of PMD should include a differential
diagnosis of partial hydatidiform mole, complete hydatidiform
mole, and recurrent hydatidiform mole. Partial hydatidiform mole
is caused by diandric triploidy [27,28]. Partial hydatidiform mole is
typically associated with a 2:1 ratio of paternal:maternal haploid
genomes due to diandric triploidy and has a positive CDKN1C
(P57KIP2) immunostaining due to the presence of a maternal allele.
The CDKN1C (P57KIP2) gene is maternally expressed and paternally
imprinted, and a positive P57KIP2 immunostaining indicates the
presence of a functional maternal allele. Complete hydatidiform
mole is typically associated with diandric diploidy, without a
maternal contribution to the genome [29], andmay have a negative
P57KIP2 immunostaining [30]. However, in some cases of complete
hydatidiform mole, a positive P57KIP2 immunostaining still exists
due to the retention of a maternal chromosome 11 [31,32]. Recur-
rent hydatidiformmole can occur in an autosomal recessive pattern
in women with recurrent miscarriage and complete hydatidiform
mole. Recurrent hydatidiform mole-1 (OMIM 231090) is caused by
homozygous or compound heterozygous mutations in NLRP7
(OMIM 609661) at 19q13 [33,34]. Recurrent hydatidiform mole-2
(OMIM 614293) is caused by homozygous or compound heterozy-
gous mutations in KHDC3L (OMIM 611687) at 6q13 [35,36].
Bourque et al [19] suggested the utility of quantitative methyl-
ation assays at imprinted genes for the diagnosis of fetal and
placental disorders. Our presentation additionally shows that MS-
MLPA, methylation-speciﬁc PCR, and QF-PCR are useful for rapid
screening of methylation alterations and androgenetic/biparental
mosaicism in PMD.
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